Novel immunotherapy for adult T-cell leukemia/lymphoma: Targeting aurora kinase A

Nicholas Paul Casey; Hiroshi Fujiwara; Toshiki Ochi; Masaki Yasukawa

doi:10.1080/2162402X.2016.1239006

Novel immunotherapy for adult T-cell leukemia/lymphoma: Targeting aurora kinase A

Oncoimmunology. 2016 Oct 7;5(11):e1239006. doi: 10.1080/2162402X.2016.1239006. eCollection 2016.

Authors

Nicholas Paul Casey¹, Hiroshi Fujiwara¹, Toshiki Ochi¹, Masaki Yasukawa¹

Affiliation

¹ Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime University , Toon, Ehime, Japan.

Abstract

Adult T-cell leukemia/lymphoma is caused by infection with HTLV-1, following a long latent period. Immunotherapy targeting Aurora kinase A, a tumor-associated antigen over-expressed in adult T-cell leukemia/lymphoma, holds great therapeutic potential. We review the evidence in favor of a therapeutic strategy combining vaccination and TCR-gene transfer against this target.

Keywords: Adult T-cell leukemia/lymphoma; T-cell receptor gene; aurora kinase A; engineered T cell; immunotherapy.